Intravenous Infusion of Umbilical Cord Blood as an Adjunctive Treatment for Alzheimer's Disease

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Alzheimer Disease (AD)
Interventions
BIOLOGICAL

Intravenous infusion of mononuclear cells from umbilical cord blood

When performing cell infusion, it is essential to use an infusion set and follow the standard blood transfusion procedures. Before, during, and after the infusion, monitor the patient's body temperature, pulse, breathing, and blood pressure. When infusing cells, first flush the tube with 20-30 ml of 0.9% sodium chloride, and start the infusion at a rate of 20-30 drops per minute. After half an hour, if there are no adverse reactions, increase the rate to 30-50 drops per minute. During the cell infusion process, gently shake the cell bag once every 15 minutes. After the infusion is completed, flush the cell preservation bag with 20 ml of 0.9% sodium chloride and gently shake it. After that, use 0.9% sodium chloride to rinse the infusion set to remove the cells completely, to ensure the quantity of cell infusion.

DRUG

Conventional medical treatment:donepezil, rivastigmine or galantamine

The treatment is carried out using drugs such as cholinesterase inhibitors (ChEI) which are suitable for mild to moderate Alzheimer's disease. For example, donepezil, rivastigmine, galantamine, etc. The frequency and dosage of drug administration should be in accordance with the instructions provided by the drug manufacturer.The patient should maintain the stability of the medication regimen throughout the entire study period.

Trial Locations (1)

230000

RECRUITING

The First Affiliated Hospital of the University of Science and Technology of China, Hefei

All Listed Sponsors
collaborator

Shandong Qilu Stem Cell Engineering Co., Ltd.

UNKNOWN

lead

Anhui Provincial Hospital

OTHER_GOV

NCT07208344 - Intravenous Infusion of Umbilical Cord Blood as an Adjunctive Treatment for Alzheimer's Disease | Biotech Hunter | Biotech Hunter